Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Abstract Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are the latest and a vital treatment option for non-small cell lung cancer (NSCLC) patients. Although EGFR-sensitive mutations are an indication for third-generation EGFR-TKI therapy, 30% of NSCLC patie...

Full description

Saved in:
Bibliographic Details
Main Authors: Ning Lou, Ruyun Gao, Yuankai Shi, Xiaohong Han
Format: Article
Language:English
Published: Nature Portfolio 2024-12-01
Series:Scientific Data
Online Access:https://doi.org/10.1038/s41597-024-04169-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items